


☐

I'm not robot


reCAPTCHA

Continue

Rectal cancer treatment guidelines nccn

The policy of disclosure of NCCNNN health education is the policy of the NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff involved in NCCN's regular education activities are expected to disclose any financial relationship to commercial interests as stipulated by the Council for the Recognition of Commercial Health Education (ACCME). In addition, all faculty presentations have been reviewed to comply with ACCME's Trade Support Standards (providers develop educational activities/interventions independent of commercial interests [SCS 1, 2 and 6] by experts on topics). Under the ACCME Standard for Commercial Assistance, individuals who do not disclose related financial relationships will be excluded from participating in CE activities as content developers, planners, or presenters. A complete list of individual relationships with external bodies is available on request. The NCCN definition of education regularly considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to influence CE content about the products or services of a commercial interest that he/she and/or a spouse or partner have a financial relationship with. NCCN's ongoing education treats related financial relationships as financial relationships in any amount that occurs within the last 12 months creating a conflict of interest. NCCN does not set a minimum amount for relationships that are significant. Inherent in any amount is the motivation to maintain or increase the value of the relationship. Faculty Disclaimers All faculty for this regular education activity are competent in matters and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Lectures by instructors may include discussions about off-label use. The department will disclose that use in question is not currently approved by the FDA for each product label. The NCCN employees listed below reveal no related financial relationships:Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, M.D.; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.Individuals Who Provided Content Development and/or Authorship Assistance:Al B. Benson III, MD, Panel Chair, has revealed that he received other financial benefits from Bristol-Myers Squibb Company, Genentech, Inc., Novartis Pharmaceuticals Corporation, ARRAY Biopharma, AVBCCC, Bayer, Dava Onc, Guardant Health, Harborside Press, LSK, Merck Sharpe and Dohme, Patient Resource, PreCOG, Springer, and Pfizer Inc.Alan P. Venook, MD, Vice President of Panel, has revealed that he is a scientific advisor to Genentech, Inc.; Halozyme, Inc.; and Roche Laboratories, Inc.Stacey Cohen, MD, Member has revealed that she received honorarias from Boston Healthcare Associates and and from Natera.Jeffrey Meyerhardt, MD, MPH, Panel Member, has revealed that he received consulting fees from Cota Healthcare and other financial interests from Taiho Pharmaceuticals Co., Ltd.Eric D. Miller, MD, PhD, Panel Member, which has revealed that he has no relevant financial relationship. Alyse Johnson-Chilla, MS, Guidance Coordinator, NCCN, has revealed that she has no financial ties involved. Lisa A. Gurski, Ph.S., Cancer Scientist/Medical Writer, NCCN, has revealed that she has no financial relationship involved. To see all conflicts of interest for the dashboard, go to [NCCN.org/disclosures/guidelinepanellisting.aspx](https://nccn.org/disclosures/guidelinepanellisting.aspx). [Tutorial] Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and monitoring for early detection of colorectal cancer and adenomatous polyps, 2008: a general guide from the American Cancer Society, the U.S. Multi-Social Task Force on Colorectal Cancer, and the American College of Radiography. CA Cancer J Clin. 2008 May-June. 58 (3):130-60. We have to go. [Tutorial] Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: Recommendations for doctors and patients from the U.S. Multi-Social Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 June 6. We have to go. [Tutorial] American Cancer Society guidelines for colorectal cancer screening. American Cancer Society. Available at . May 30, 2018; Access: February 25, 2020. [Tutorial] U.S. Preventive Services Task Force. Colorectal Cancer Screening: Recommendations of the U.S. Preventive Services Task Force. Jama. June 16, 2016. [Full text]. [Tutorial] Wilt TJ, Harris RP, Qaseem A, American College of Physicians High Value Care Task Force. Cancer screening: high-value care advice from the American College of Physicians. Ann Intern Med. 2015 May 19. 162 (10):718-25. We have to go. [Full text]. [Tutorial] Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [correction]. Am J Gastroenterol. 2009 March 104 (3):739-50. We have to go. [Tutorial] National Comprehensive Cancer Network. Guidelines for clinical practice of NCCN in oncology: Colorectal cancer screening. NCCN. Available at . Version 2.2019 — August 2, 2019; Access: February 25, 2020. [Tutorial] National Comprehensive Cancer Network. Guidelines for NCCN clinical practice in oncology: Genetic/family high risk assessment: Colorectal. NCCN. Available at . Version 3.2019 — December 13, 2019; Access: February 25, 2020. lead] Helsingen LM, Vandvik PO, Jodal HC, Agoritsas T, Lytvyn L, Anderson JC, et al. Colorectal cancer screening with stool, stool, or colonoscopy: a guide to clinical practice. BMJ. 2019 October 2. 367:5515. We have to go. [Full text]. [Tutorial] National Comprehensive Cancer Network. Guidelines for clinical practice of NCCN in oncology: Colon cancer. Available at . Version 1.2020 — December 19, 2019; Access: February 25, 2020. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Bethesda guidelines modified for non-heredogenic colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 February 18. 96 (4):261-8. We have to go. [Tutorial] Rubenstein JH, Enns R, Heidelbaugh J, Barkun A, Clinical Guidance Committee. Guidelines from the American Digestive Association Institute for the Diagnosis and Management of Lynch Syndrome. Digestion. 2015 September 149 (3):777-82. We have to go. [Full text]. [Tutorial] Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guide Working Group. Colorectal cancer family risk: ESMO Clinical Practice Guidelines. Ann Oncol. 2013 October 24 Suppl 6:73-80. We have to go. [Full text]. [Tutorial] Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Heredity Colorectal Cancer Syndrome: The American Society for Clinical Oncology Clinical Practice Guidelines for Clinical Practice confirming family-risk colorectal cancer: European Medical Oncology Society Clinical Practice Guidelines. J Clin Oncol. 2015 January 10. 33 (2):209-17. We have to go. [Full text]. [Tutorial] Syngal S, Brand RE, JM Church, Giardiello FM, Hampel HL, Burt RW, et al. ACG Clinical Guidelines: Genetic Testing and Management of Genetic Gastrointestinal Cancer Syndrome. Am J Gastroenterol. February 110 (2):223-62; test 263. We have to go. [Full text]. [Tutorial] Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommended follow-up after colonoscopy and polypectomy: Update the U.S. Multi-Social Task Force's consensus on colorectal cancer. Digestion. 2020 February 5. 143 (3):844-57. We have to go. [Tutorial] Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Bowel. February 69 (2):201-223. We have to go. [Full text]. Church J, Simmang C, Standard Task Force, American Society of Colon and Rectal Surgeons, Americas Collaboration Group on Colorectal Cancer Genetics and The American Association's Standards Committee of Colon and Rectal Surgeons. Practice parameters for the treatment of patients with heredity primarily heredity colorectal cancer (family adenomatous polyposis and heredity nonpolyposis colorectal cancer). Dis Colon Live 2003 August 46 (8):1001-12. We have to go. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD, Standard Practice Task Force of the American Association of Colorectal and Rectal Surgeons. Practice parameters for management of colon cancer. Dis Colon rectum. 2012 August 55 (8):831-43. We have to go. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, et al. Practice parameters for managing rectal cancer (modified). Dis Colon rectum. May 2013. 56 (5):535-50. We have to go. [Tutorial] Glynne-Jones R, Wyrwicz L, Tiet E, Brown G, Rödel C, Cervantes A, et al. Rectal Cancer: ESMO Clinical Practice Guide for Diagnosis, Treatment and Follow-up. Ann Oncol. 2017 July 1. 28 (suppl 4):iv22-iv40. We have to go. [Full text]. [Tutorial] National Comprehensive Cancer Network. Guidelines for clinical practice of NCCN in oncology. Rectal cancer. Available at . Version 2.2019 — May 15, 2019; Access: August 3, 2019. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. The American Society of Clinical Oncology recommends complementary chemotherapy for stage II colon cancer. J Clin Oncol. 2004 August 15. 22 (16):3408-19. We have to go. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, monitoring protocols, and primary precautions for colorectal cancer survivors: Atte topical clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2013 December 10. 31 (35):4465-70. We have to go. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guide for diagnosis, treatment and follow-up. Ann Oncol. 2013 October 24 Suppl 6:64-72. We have to go. [Tutorial] Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practical guidelines for monitoring patients after treatment for colon and rectal cancer. Dis Colon rectum. 2015 August 58 (8):713-25. We have to go. [Full text]. [Tutorial] Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy monitoring after rectal cancer rescinding: Recommendations of the U.S. Multi-Social Task Force on Colorectal Cancer. Digestion. 2016 March 150 (3):758-768.e11. We have to go. [Full text]. [Tutorial] Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular Biomarkers for Colorectal Cancer Assessment: Guidelines from the American Society of Clinical Pathology, American College of Pathology, Molecular Pathology Association, and American Society of Clinical Oncology. Arch Pathol Lab Med. February 6, 2017. 19 (2):187-225. We have to go. [Tutorial] Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for managing patients with metastase colorectal cancer. Ann Oncol. 2016 August 27 (8):1386-422. We have to go. [Full text]. [Tutorial] COVID-19 guidelines on the classification of colorectal cancer patients. College of Surgeons United. Available at . March 24, 2020; Access: April 8, 2020. [Tutorial] Cancer surgery during COVID-19: COVID-19: Message from SSO President and President-elect. Surgical Oncology Association. Available at . March 23, 2020; Access: April 10, 2020. 2020.